Please assess the completion status of the following clinical trial:

Trial Title: HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proved diagnosis of colorectal cancer.~* Unresectable peritoneal metastases and primary tumor proved at surgery.~* No evidence of distant metastases.~* Have not received radiotherapy, chemotherapy or immunotherapy.~* ECOG score: 0\~2.~* Written informed consent is obtained prior to commencement of trial treatment.~Exclusion Criteria:~* Existence of distant metastasis outside the abdomen.~* Any previous radiotherapy, chemotherapy or immunotherapy.~* Active systemic infections.~* Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.~* Female patients who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).